NCT06607185 2026-03-13A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsEli Lilly and CompanyPhase 1 Active not recruiting750 enrolled
NCT06561685 2026-02-10A Study of LY4050784 in Participants With Advanced or Metastatic Solid TumorsEli Lilly and CompanyPhase 1 Recruiting340 enrolled
NCT04198766 2025-12-18Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)Inhibrx Biosciences, IncPhase 1/2 Active not recruiting296 enrolled
NCT05014815 2025-09-16Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung CancerBeiGenePhase 2 Completed272 enrolled 17 charts
NCT03884556 2025-07-02TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced CancersTrishula Therapeutics, Inc.Phase 1 Completed56 enrolled 19 charts
NCT03678883 2024-11-079-ING-41 in Patients with Advanced CancersActuate Therapeutics Inc.Phase 2 Active not recruiting350 enrolled